- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.07. | Medicenna stock price target maintained at $2.50 by H.C. Wainwright | 2 | Investing.com | ||
| 26.06. | Medicenna Therapeutics Corp. GAAP EPS of -C$0.22 | 1 | Seeking Alpha | ||
| 26.06. | Medicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights | 185 | GlobeNewswire (Europe) | MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer... ► Artikel lesen | |
| 11.06. | Medicenna Therapeutics Corp: Medicenna receives two U.S. patents | 1 | Stockwatch | ||
| 03.06. | Medicenna Therapeutics Corp: Medicenna highlights MDNA11 melanoma trial data | 3 | Stockwatch | ||
| 03.06. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 29.05. | Medicenna Therapeutics Corp: Medicenna Therapeutics closes $4.44M public offering | 1 | Stockwatch | ||
| MEDICENNA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.05. | Medicenna Therapeutics Corp.: Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs | 1 | GlobeNewswire (USA) | ||
| 22.05. | Medicenna Therapeutics Corp: Medicenna files prospectus for $5-million offering | 1 | Stockwatch | ||
| 22.05. | Medicenna Therapeutics Corp.: Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet | 3 | GlobeNewswire (USA) | ||
| 19.05. | Medicenna Therapeutics Corp: Medicenna sets out terms of public offering | 1 | Stockwatch | ||
| 19.05. | Stocks in Play: Medicenna Therapeutics Corp. | 1 | Baystreet.ca | ||
| 19.05. | Medicenna prices public offering at $0.50 per unit | 5 | Investing.com | ||
| 13.05. | Medicenna launches public offering to fund clinical programs | 2 | Investing.com | ||
| 13.05. | Medicenna launches marketed public offering of securities | 1 | Seeking Alpha | ||
| 13.05. | Medicenna Therapeutics Corp.: Medicenna Announces the Launch of a Marketed Public Offering of Securities | 1 | GlobeNewswire (USA) | ||
| 12.05. | Stocks in Play: Medicenna Therapeutics Corp. | 2 | Baystreet.ca | ||
| 12.05. | Medicenna Therapeutics Corp.: Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma | 181 | GlobeNewswire (Europe) | NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase... ► Artikel lesen | |
| 21.04. | Medicenna Therapeutics Corp: Medicenna releases MDNA113 preclinical data | 1 | Stockwatch | ||
| 21.04. | Medicenna Therapeutics Corp.: Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026 | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,670 | +10,62 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| VIRAX BIOLABS GROUP | 9,300 | +192,45 % | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,820 | +2,13 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,40 | +0,11 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| ABSCI | 11,355 | +2,30 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 62,28 | -8,05 % | Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101 | ||
| BEAM THERAPEUTICS | 36,120 | -2,06 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| VERA THERAPEUTICS | 42,180 | -0,59 % | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer... ► Artikel lesen | |
| ERASCA | 19,510 | +3,39 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 47,110 | +1,75 % | Oppenheimer initiates Edgewise Therapeutics stock with outperform rating | ||
| RECURSION PHARMACEUTICALS | 3,795 | +2,02 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,670 | +0,60 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen | |
| ALUMIS | 30,240 | +1,68 % | Alumis Aktie erreicht Rekordhoch bei 30,67 USD | ||
| RELAY THERAPEUTICS | 20,190 | +2,85 % | JPMorgan stuft Relay Therapeutics zum Start mit "Overweight" ein | ||
| CG ONCOLOGY | 73,24 | +4,92 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen |
MEDICENNA THERAPEUTICS CORP gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICENNA THERAPEUTICS CORP finden Sie auf Wallstreet Online.